Matthew D. Silverman

Cooley advised Avid Bioservices (Nasdaq: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, on its definitive merger agreement to be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion.

Cooley advised Cannae Holdings (NYSE: CNNE), an investment firm with stakes in restaurants, technology-enabled healthcare services, financial services and more, on its partnership with KDSA Investment Partners to acquire a majority stake in The Watkins Company, a 156-year-old American heritage brand renowned for its high-quality flavoring products.

Cooley advised Candid Therapeutics, a biotechnology company dedicated to developing potentially transformative drugs to address autoimmune diseases, on its $370 million debut capital raise and three-way merger with Vignette Bio and TRC 2004.

Cooley advised Adaptive Phage Therapeutics, a US-based, privately held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, on its definitive merger agreement with BiomX, a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria.

Cooley advised Tourmaline Bio, a late-stage clinical biotechnology company, on its merger agreement with Talaris Therapeutics, including a concurrent private placement.